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Abstract
Purpose The increasing number of women living longer with
potential side effects of breast cancer treatment highlights the
need of a comprehensive assessment of its burden. Therefore,
we aimed to quantify the relation between different breast
cancer treatments and sleep quality 1 year after diagnosis.
Methods A cohort of 502 newly diagnosed breast cancer pa-
tients was prospectively followed. Sleep quality was evaluated
with the Pittsburgh Sleep Quality Index (PSQI), at baseline
and at the 1-year follow-up. Odds ratios (OR) were computed
to quantify the association between patient characteristics and
poor sleep quality (PSQI score >5) at baseline, and relative
risks (RR) were computed for the association between treat-
ments and the occurrence of poor sleep quality at 1 year.
Results A total of 60.2% of the patients had poor sleep quality
before breast cancer treatments, especially those with anxiety
[OR = 2.86, 95% confidence interval (95%CI) 1.92 to 4.27] or
depression (OR = 5.25, 95%CI 2.01 to 13.67). Radiotherapy
increased the risk of poor sleep quality at 1 year (RR = 3.71,
95%CI 1.15 to 11.96, for a cumulative dose >50 Gy) and there
was a tendency for a higher risk in those submitted to chemo-
therapy, although not statistically significant.
Conclusions Our study shows that sleep disturbances are fre-
quent before cancer treatment and confirms their co-
occurrence with other medical conditions, such as anxiety
and depression. Different breast cancer treatments increase
the risk of impaired sleep quality, therefore contributing to
the global disability associated with cancer treatments.
Keywords Antineoplastic protocols . Breast cancer . Quality
of life . Radiotherapy . Sleep
Introduction
Breast cancer is the second most common cancer in the world
and the most frequent among women, with an estimated 1.7
million new cancer cases diagnosed in 2012 [1]. During the
last few decades, survival has improved as a result of earlier
diagnoses and the use of more effective and aggressive treat-
ments [2], surpassing 80% inmost developed settings [3]. The
growing number of women living for longer periods with
potential sequelae of breast cancer treatment makes it the
worldwide leading cause of years lived with disability due to
oncological diseases in women [4], which highlights the need
of a comprehensive assessment of the burden associated with
breast cancer treatment among survivors.
Poor sleep quality is an important contributor to low health-
related quality of life [5, 6] and is estimated to affect up to 70%
of breast cancer patients [7], depending on the method of sleep
assessment and study design used. Although a high proportion
of breast cancer patients may present sleep disturbances be-
fore beginning treatment [8, 9], cancer treatment has been
associated with the occurrence of sleep disturbances among
women with breast cancer [10, 11]. In a recent systematic
review, women submitted to chemotherapy (CTX), as well
as radiotherapy, tended to report higher levels of sleep
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disturbances; inconsistent findings were observed regarding
the different options for surgery and the use of hormonal treat-
ment [12]. The only prospective study included in this review
evaluated patients before surgery and followed them for
6 months, concluding that adjuvant CTX was associated with
gradual increases in sleep disturbances that peaked at the third
month and then decreased until 6 months after surgery [13].
Although previous studies have addressed the relation be-
tween breast cancer treatments and sleep disturbances, the
achievement of more robust findings was hampered by limi-
tations such as the absence of control for confounding, the use
of non-standardizedmeasures to evaluate sleep quality and the
scarcity of longitudinal analyses taking into account sleep
quality of the patients at baseline, in addition to some lack of
detail in the description of all treatments [12]. Data from pro-
spective studies with an evaluation of participants prior to
treatments and providing a detailed assessment of the effect
of breast cancer treatments may contribute to a more accurate
characterization of sleep quality determinants. Therefore, we
aimed to quantify the relation between different breast cancer
treatments and sleep quality 1 year after breast cancer diagno-
sis, using a contemporary prospective cohort of women in the
early stages of the disease, and with the baseline evaluation
performed before treatments.
Methods
We conducted a prospective study with newly diagnosed
breast cancer women, followed for 1 year, as described in
detail elsewhere [14].
Patients and settings
Participants were consecutively recruited in 2012, among pa-
tients with a breast cancer diagnosed within the previous
3 months and proposed for surgery, aged 18 years or older,
and admitted to the Breast Clinic of the Portuguese Institute of
Oncology of Porto. We excluded those previously treated with
CTX and/or radiotherapy in the chest or axillary areas for
other primary cancers, those that had received any treatment
for breast cancer before, and those with a high probability of
cognitive impairment (a score lower than 17, or lower than 16
for women over 65 years, in the Montreal Cognitive
Assessment) [15].
The cohort included 506 patients with incident breast can-
cer, from whom 502 (99.2%) completed the 1-year follow-up
evaluation without missing data in the outcome studied (one
patient died, two patients abandoned the study, and one patient
had missing information on sleep quality at 1 year) and were
therefore included in the present analysis.
Data collection
For the analysis, data were collected in two distinct moments:
at baseline (after diagnosis but before any cancer treatment)
and 1 year after enrollment. The median time [percentile 25,
percentile 75 (P25, P75)] between diagnosis (date of the first
histological confirmation) and the baseline evaluation was
25 days (18–32).
At baseline, sociodemographic data were collected using a
structured questionnaire and clinical records were reviewed
for cancer stage and menopausal status. Cancer stage was
classified according to the American Joint Committee on
Cancer Staging Manual [16]. When menopausal status was
not specified, all women older than 60, women who
underwent a bilateral ovariectomy, and those with an intact
uterus and amenorrheic for at least 1 year prior to the breast
cancer diagnosis were classified as postmenopausal, other-
wise as premenopausal [17]. For analysis, age was catego-
rized, using the mean of the distribution among all participants
as the cutoff (≤55 and >55 years). Education was collected as
a continuous variable considering the complete years of
schooling and later categorized as 4 years or less (primary
education), 5 to 9 years (lower secondary school), and 10 years
or more (upper secondary and post-secondary education).
At the 1-year follow-up, clinical records were reviewed for
cancer treatments performed during the previous year.
The Hospital Anxiety and Depression Scale (HADS) was
used to evaluate anxiety and depression at baseline [18, 19].
Scores for each subscale range from 0 to 21, and a score
greater than or equal to 11 for each was considered to be
indicative of clinically significant anxiety and/or depression,
as applicable [18, 20].
Sleep quality at baseline and at the 1-year follow-up evalu-
ation was assessed using the Pittsburgh Sleep Quality Index
(PSQI) [21, 22]. The PSQI consists of 19 questions measuring
seven components, including subjective sleep quality, sleep
latency, sleep duration, habitual sleep efficiency, sleep distur-
bances, use of sleep medication, and daytime dysfunction.
Items are summed to provide a global sleep quality score rang-
ing from 0 to 21, with higher scores indicating worse sleep
quality; a score greater than 5 indicates poor sleep quality [21].
Statistical analysis
Crude and adjusted odds ratios (OR), and corresponding 95%
confidence intervals (95%CI), for the relation between
sociodemographic and clinical characteristics of the patients,
and the presence of poor sleep quality at baseline were com-
puted using logistic regression. Relative risks (RR) and
95%CI were computed using the Poisson regression, taking
into account the time between the baseline and the 1-year
follow-up evaluation, to identify predictors of improvement
(PSQI ≤5) or deterioration (PSQI >5) of sleep quality, in those
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with poor and good sleep quality at baseline, respectively.
Variables included in each model are those considered, as a
result of previous studies or expert knowledge, to be associat-
ed with both the exposure and the outcome, but influenced by
neither, and are described in the footnotes of the correspond-
ing table or figure. Whenever overlapping treatments were
considered in the multivariable models, each treatment was
included as an independent dichotomous variable.
Sample characteristics are presented as counts and propor-
tions for categorical variables, mean and standard deviation
(SD) for quantitative variables with an approximately sym-
metrical distribution, and median (P25-P75) for quantitative
variables with a markedly asymmetrical distribution.
Statistical analyses were conducted using STATA®, version
11.2 (StataCorp, College Station, TX, USA).
Results
Patients’ characteristics
The main sociodemographic and clinical characteristics of the
patients are presented in Table 1. At baseline, 47.2% had more
than 55 years of age and 71.5% had less than 10 years of edu-
cation. Most women were diagnosed with cancer stage 0 or I
(53.6%). Few participants (3.8%) did not undergo adjuvant/
neoadjuvant therapy with 14.9% performing only one type.
Among the latter, 0.6, 1.4, and 12.9% performed chemotherapy,
radiotherapy, and endocrine therapy, respectively. A total of
81.3% of the participants underwent at least two types of treat-
ments; the most common combinations were radiotherapy and
endocrine therapy (62.0%), chemotherapy and endocrine thera-
py (49.8%), and chemotherapy and radiotherapy (49.6%).
The mean (SD) time between the baseline and the 1-year
follow-up evaluation was 379.0 days (28.6). Among those
performing surgery, chemotherapy, radiotherapy, or brachyther-
apy, the 1-year follow-up evaluation occurred 337.2 (58.5),
205.7 (44.5), 164.8 (73.2), and 195.0 days (82.7), respectively,
after the end of the treatment. Those performing chemotherapy
and radiotherapy were under treatment for a median (P25-P75)
of 105 days (103–113) and 34 days (32–42), respectively.
Factors associated with poor sleep quality at baseline
At baseline, the median (P25, P75) PSQI score was 7 (4, 10),
with 60.2% of the patients with poor sleep quality before breast
cancer treatment (PSQI score >5). A total of 59.8% reported
sleep-onset latency or wakefulness after a sleep onset of more
than 30 min with a frequency of at least three times a week.
The association between different patient characteristics and
the presence of poor sleep quality at baseline is reported in
Table 2. Anxiety and depression were associated with an odds
of poor sleep quality approximately three and fivefold higher,
respectively. No statistically significant associations were ob-
served for age, education, menopausal status, and cancer stage.
Sleep quality during the first year after diagnosis
The median (P25, P75) PSQI score variation between the
baseline and the 1-year follow-up evaluation was 0 (−2, 2).
However, 47.2% patients got worse (an increase in the PSQI
score by at least one point), especially those with good sleep
quality prior to treatment (58.5% with good sleep quality ver-
sus 39.7% with poor sleep quality, P ≤ 0.001) and 39.6%
showed an improvement in their sleep quality, especially those
with poor sleep quality at baseline (20.5% with good sleep
quality versus 52.3% with poor sleep quality, P ≤ 0.001). A
total of 31.9 and 39.4% of the participants reported using sleep
medication at least three times per week in the preceding
month, at baseline and at the 1-year follow-up, respectively.
Predictors of the variation of sleep quality
Figure 1 depicts the adjusted RR for the relation between dif-
ferent patient characteristics and the occurrence of poor sleep
quality (PSQI >5) at 1 year, among those with good sleep
quality at baseline. Radiotherapy was significantly associated
with a higher risk of poor sleep quality (P value for
trend = 0.032) and there was a tendency for a higher risk among
those submitted to mastectomy and those that underwent CTX,
although differences were not statistically significant.
Figure 2 depicts the adjusted RR for the relation between
different patient characteristics and the occurrence of good
sleep quality (PSQI ≤5) at 1 year, among those with poor sleep
quality at baseline. There was a tendency for a higher risk of
good sleep quality in more educated women (P value for
trend = 0.008) and mastectomy was associated with a lower
risk of good sleep quality, though not statistically significant.
Discussion
This study shows a high prevalence of poor sleep quality
before breast cancer treatments and its strong association with
anxiety and depression. Among patients with poor sleep qual-
ity at baseline, education was positively associated with an
improvement in sleep quality. Among patients with good
sleep quality at baseline, radiotherapy increased the risk of
poor sleep quality during the follow-up.
Although direct comparisons are difficult due to the hetero-
geneous characteristics of the patients evaluated and the use of
different methods to assess sleep quality and/or to define the
outcomes, our study yielded a prevalence of poor sleep quality
prior to treatments approximately twice as high as previous
estimates of insomnia [8, 9]. In a study from Ireland [8],
25.5% of the women awaiting breast surgery as a first-line
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treatment presented insomnia (evaluated using the Insomnia
Severity Index). In Canada [9], a study conducted among cancer
patients during the perioperative phase, in which some women
had already been submitted to surgery, showed that 36.0% of
those with breast cancer had insomnia syndrome (assessed
using an adaptation of the Insomnia Interview Schedule).
Table 1 Sociodemographic and
clinical characteristics of the
patients (N = 502)
[N (%)]
Age, years ≤55 265 (52.8)
>55 237 (47.2)
Education, years ≤4 216 (43.0)
5–9 143 (28.5)
≥10 143 (28.5)
Anxietya 190 (37.9)
Depressionb 41 (8.2)
Poor sleep qualityc 302 (60.2)
Menopausal statusd Premenopausal 208 (43.2)
Postmenopausal 273 (56.8)
Cancer stage 0 34 (6.8)
I 235 (46.8)
II 155 (30.9)
III 75 (14.9)
IV 3 (0.6)
Surgerye
Breast surgery Breast-conserving 249 (49.6)
Mastectomy 252 (50.2)
Only axillary surgery 1 (0.2)
Axillary surgery SLNB 315 (64.7)
ALND 172 (35.3)
CTX 298 (59.4)
Timing Neoadjuvant 34 (11.4)
Adjuvant 264 (88.6)
CTX schemes Doxorubicin + cyclophosphamide (± docetaxel) 92 (30.9)
Doxorubicin + cyclophosphamide + paclitaxel 1 (0.3)
Cyclophosphamide + docetaxel 2 (0.7)
Carboplatin + docetaxel 1 (0.3)
5-FU + epirubicin + cyclophosphamide (± docetaxel) 201 (67.4)
5-FU + cyclophosphamide + methotrexate 1 (0.3)
Other adjuvant treatments Radiotherapy 366 (72.9)
Brachytherapy 95 (18.9)
Endocrine therapyf 421 (83.9)
Immunotherapyf 68 (13.6)
ALND axillary lymph node dissection, CTX chemotherapy, SLND sentinel lymph node dissection, 5-FU 5-
fluorouracil
a Defined as a score greater than or equal to 11 in the anxiety subscale of the Hospital Anxiety and Depression
Scale; N = 501 due to missing data
b Defined as a score greater than or equal to 11 in the depression subscale of the Hospital Anxiety and Depression
Scale
c Defined as a score greater than 5 in the Pittsburgh Sleep Quality Index
dN = 481 due to missing data
e Patients who had both mastectomy and breast-conserving surgery are reported as mastectomy and patients who
had both ALND and SLNB are reported as ALND
fAll patients began this treatment during the first year of follow-up and remained under treatment at the 1-year
follow-up evaluation
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Our findings of greater odds of poor sleep quality at base-
line among those with anxiety and depression are consistent
with the literature showing that anxiety and depression are
associated with the presence of sleep disturbances in the gen-
eral population [23–25] and in breast cancer patients [26, 27].
In fact, insomnia symptoms are one of the diagnostic criteria
for several mood and anxiety disorders [28]. Conversely, the
presence of a psychiatric disorder (e.g., depressive or anxiety)
has been described as a predisposing factor for the develop-
ment of sleep problems [29]. However, though it was not
surprising to find an association between these symptoms,
our cross-sectional data analysis precludes the assumption of
the direction of an association between anxiety or depression
and poor sleep quality prior to treatments.
Although fatigue was not evaluated in the present study, it
may have played an important role in the prevalence and in the
occurrence of poor sleep quality during the first year after
cancer diagnosis. In fact, a growing number of recent studies
support that fatigue may co-occur with depression and sleep
disturbances as part of a symptom cluster in breast cancer
patients [30–33]. Berger et al. examined patterns of circadian
rhythms and their relationship with fatigue, anxiety, and de-
pression and concluded that disrupted patterns of circadian
rhythms were associated with distressing fatigue and depres-
sive symptoms during chemotherapy [30]. Ho et al. investi-
gated the co-occurrence of and interrelations between the
three symptoms prior to, after and 6 to 8 months following
adjuvant chemotherapy, and their findings revealed moderate
to large bivariate associations between symptoms, prior to and
following treatment [31]. Bower et al. examined the impact of
fatigue on various components of health-related quality of life
in a sample of breast cancer survivors 1 to 5 years after initial
cancer diagnosis and concluded that more severe fatigue was
associated with significantly higher levels of depression and
sleep disturbance [32]. Finally, through a systematic review,
Brown et al. confirm the association of fatigue with depression
Table 2 Association between
sociodemographic and clinical
characteristics of the patients and
poor sleep quality at baseline
(N = 502)
Patients with poor sleep qualitya
at baseline [N (%)]
Crude OR (95%CI) Adjusted OR (95%CI)
Age (years)
≤55 154 (58.1) 1 (ref.)
>55 148 (62.4) 1.20 (0.84 to 1.72)
Education (years)
≤4 130 (60.2) 1 (ref.) 1 (ref.)
5–9 92 (64.3) 1.19 (0.77 to 1.85) 1.31 (0.82 to 2.10)b
≥10 80 (55.9) 0.84 (0.55 to 1.29) 0.93 (0.58 to 1.48)b
Anxiety at baselinec
No 160 (51.4) 1 (ref.) 1 (ref.)
Yes 142 (74.7) 2.79 (1.88 to 4.15) 2.86 (1.92 to 4.27)d
Depression at baselinee
No 266 (57.7) 1 (ref.) 1 (ref.)
Yes 36 (87.8) 5.28 (2.03 to 13.70) 5.25 (2.01 to 13.67)d
Menopausal status at baselinef
Premenopausal 121 (58.2) 1 (ref.) 1 (ref.)
Postmenopausal 171 (62.6) 1.21 (0.83 to 1.74) 1.19 (0.62 to 2.27)b
Cancer stage
0/I 169 (62.8) 1 (ref.) 1 (ref.)
II 85 (54.8) 0.72 (0.48 to 1.07) 0.71 (0.47 to 1.06)g
III/IV 48 (61.5) 0.95 (0.56 to 1.59) 0.94 (0.56 to 1.60)g
OR odds ratio, 95%CI 95% confidence interval
a Defined as a score greater than 5 in the Pittsburgh Sleep Quality Index
bAdjusted for age
c Defined as a score greater than or equal to 11 in the anxiety subscale of the Hospital Anxiety and Depression
Scale; N = 501 due to missing data
d Adjusted for age, education, and cancer stage
e Defined as a score greater than or equal to 11 in the depression subscale of the Hospital Anxiety and Depression
Scale
fN = 481 due to missing data
g Adjusted for age and education
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and anxiety but emphasize the need of longitudinal studies to
better delineate its directionality [33].
Previous results described a tendency for higher levels of
sleep disturbance in women submitted to radiotherapy when
compared to those not submitted to this type of treatment, though
results were not statistically significant [26, 27, 34]. We found a
nearly fourfold higher risk of poor sleep quality among women
submitted to the highest doses of radiotherapy; the impact of
physical side effects of radiation, such as skin reactions and pain,
which have been demonstrated to increase with the dose admin-
istered [35], could be precipitating factors for sleep disturbances
in those with good sleep quality prior to treatment.
Although not statistically significant, we found a tendency
for higher levels of poor sleep quality among women submit-
ted to CTX, which is in accordance with previous results [13,
36, 37]; the daily life disruption related with the psychological
(e.g., worries, anxiety, and depression related with anticipation
of side effects) and physical (e.g., hot flashes, fatigue, nausea,
and vomiting) side effects of treatment could, at least in part,
explain these results [29, 38].
The relationship between education and sleep disturbance
in breast cancer patients has not been consistent across studies
[34, 39, 40]. Nevertheless, our findings may reflect the fact
that more educated women may have better knowledge re-
garding breast cancer prognosis and treatment-related disabil-
ity that can contribute to minimize the physical and psycho-
logical impact of cancer diagnosis and cancer treatment on
sleep quality.
The present study provides a comprehensive assessment of
the impact of breast cancer treatment on sleep quality. Its
major strengths are the longitudinal analysis of sleep quality,
with an evaluation prior to treatments, the nearly complete
follow-up of the cohort, the use of standardized sleep-
specific measures, and the use of HADS to evaluate anxiety
and depression. The fact that HADS does not specifically take
into account symptoms such as loss of appetite, fatigue, and
sleep disturbance, which may result from either depression or
physical illness, is one of the major strengths of this instru-
ment, therefore preventing false positives due to underlying
medical conditions [18]. Since sleep disturbances are not di-
rectly contributing to the HADS score, this results in a more
meaningful assessment of the association between sleep qual-
ity and depression in our analysis. However, some limitations
need to be addressed. Our study was based on a cohort of a
large number of participants, which precluded the use of ob-
ject ive measures of sleep quali ty (act igraphy or
Fig. 1 Association between
sociodemographic and clinical
characteristics of the patients and
the occurrence of poor sleep
quality at 1 year, among those
with good sleep quality at
baseline (N = 200).ALND axillary
lymph node dissection, CTX
chemotherapy, SLNB sentinel
lymph node dissection, 5-FU 5-
fluorouracil. aComputed among
those with good sleep quality at
baseline (score equal or lower
than 5 in the Pittsburgh Sleep
Quality Index). bDefined as a
score greater than or equal to 11 in
the anxiety subscale of the
Hospital Anxiety and Depression
Scale. cDefined as a score greater
than or equal to 11 in the
depression subscale of the
Hospital Anxiety and Depression
Scale. dAdjusted for age.
eAdjusted for age, education, and
cancer stage. fAdjusted for age
and education. gAdjusted for age,
education, cancer stage, and
breast and axillary surgery.
hAdjusted for age, education,
cancer stage, and menopausal
status
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polysomnography). Nevertheless, according to the recom-
mendations for a standard research assessment of sleep or
insomnia symptoms in epidemiological studies, the PSQI is
one of the measures recommended to evaluate these outcomes
and has been demonstrated good psychometric properties
[41]. We evaluated sleep quality up to 1 year of follow-up,
which limits the assessment of the long-term burden of breast
cancer treatments (e.g., breast reconstruction). Nevertheless, a
longer follow-up of these patients is being conducted, to fur-
ther improve the information provided by this study.
In conclusion, our study shows that sleep disturbances are
frequent even before cancer treatments and support its co-
occurrence with other important medical conditions, such as
anxiety and depression. In addition, our findings highlight the
effect of different breast cancer treatments in the trajectories of
sleep quality during the first year after diagnosis. These results
emphasize the importance of monitoring sleep quality prior to
and during treatments, and the pertinence of treatment for co-
occurring disorders, as part of a strategy to improve sleep
quality prior to the beginning of treatments. Additional re-
search is needed to evaluate the existence of different patterns
of sleep quality among women with breast cancer in the long
term and to clarify the role of other important side effects of
breast cancer treatments as mediators of the impact of treat-
ments on sleep quality.
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